TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01002339
Drug: Tacrolimus with rapid steroid withdrawal
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.
Study: NCT01002339
Drug: Tacrolimus with steroids minimization
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.
Study: NCT01002339
Drug: CsA with steroid minimization
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d
Study: NCT04881994
Drug: Finerenone (BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single oral dose of finerenone given as 5 mg immediate release (IR) tablet.
Study: NCT02564094
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
Study: NCT00508872
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
Study: NCT00508872
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
Study: NCT00921375
Drug: TULY
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
Study: NCT00508872
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
Study: NCT00993382
Drug: Celivarone
Normalized name: Celivarone
DrugBank: Celivarone (DB16012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00993382
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00411892
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 45 mg/day.
Study: NCT01911546
Drug: everolimus + low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are supplied everolimus (Zortress) + prograf
Study: NCT03693846
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion per institutional guidelines and the Package Insert
Study: NCT03693846
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion per institutional guidelines and the Package Insert
Study: NCT01841411
Drug: N-Acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
Study: NCT01841411
Drug: metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
Study: NCT01958372
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01958372
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01958372
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01081652
Drug: Micronised Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
Study: NCT01081652
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
Study: NCT01907854
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
Study: NCT01907854
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
Study: NCT02682524
Drug: Pelubiprofen CR 45mg tab.
DrugBank: Pelubiprofen (DB12150)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02682524
Drug: Aceclofenac 100mg tab.
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00494728
Drug: Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
Study: NCT03149315
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 420mg, PO once daily for 2-7 days
Study: NCT02118584
Drug: Etrolizumab
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
Study: NCT00821795
Drug: insulin aspart protamine/insulin aspart 70/30 mix
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
Study: NCT04277897
Drug: Hepenofovir Fumarate Tablets Single Dose
Normalized name: budesonide / formoterol fumarate Metered Dose Inhaler [Symbicort]
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablet; Subjects will receive either a single dose of Hepenofovir Fumarate Tablets on Day 1 only (SAD), once daily dosing of HTS starting on Day 1 through Day 7 (MAD).
Study: NCT04277897
Drug: Hepenofovir Fumarate Tablets Dose4
Normalized name: fumaric acid Oral Tablet
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tabet; Subjects will receive Hepenofovir Fumarate Tablets Dose4 on Day 1 in fast condition, then receive Hepenofovir Fumarate Tablets Dose4 on Day 8 in fed condition.
Study: NCT01151865
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4.
Study: NCT01090648
Drug: etravirine
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
Study: NCT02653131
Drug: Dipeptidyl peptidase-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02766023
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
Study: NCT00004169
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004169
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03355872
Drug: HLX01
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biosimilar of Rituximab
Study: NCT00589823
Drug: Immediate release morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
Study: NCT01296581
Drug: X-82
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01319422
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison of different dosages and schedules of drug
Study: NCT03730064
Drug: N-acetyl cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental medication with N-acetyl cysteine (NAC) for six weeks
Study: NCT04130633
Drug: THC
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure THC vapor
Study: NCT04130633
Drug: Alpha-Pinene
Normalized name: Alpha-Pinene
DrugBank: alpha-Pinene (DB15573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure alpha-pinene vapor
Study: NCT01711073
Drug: Mobilization with G-CSF and Mozobil
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with drugs for mobilization of MSCs
Study: NCT04442295
Drug: STK-001 - Single Ascending Doses
Normalized name: STK-001
DrugBank: Zorevunersen (DB16912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
Study: NCT04442295
Drug: STK-001 - Multiple Ascending Doses
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
Study: NCT04705831
Drug: Ruconest
Normalized name: Ruconest
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 Esterase Inhibitor
Study: NCT02476253
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
Study: NCT04734028
Drug: Clopidogrel Tablets
Normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily
Study: NCT00231322
Drug: praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03219723
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan tablets
Study: NCT03219723
Drug: Amoxicillin hydrate
Normalized name: amoxicillin anhydrous
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin hydrate (potency)
Study: NCT00525499
Drug: ASC-J9 cream
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application to the face twice daily for 12 weeks.
Study: NCT03219723
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole
Study: NCT02631408
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally, intrawound applied vancomycin powder
Study: NCT03343665
Drug: Nivolumab 40 mg in 4 ml Injection
Normalized name: nivolumab 40 MG in 4 ML Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
Study: NCT01939236
Drug: traditional Chinese medicine
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
Study: NCT02425774
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02796170
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg pill taken once daily
Study: NCT04429711
Drug: Ivermectin Oral Product
Normalized name: ivermectin Oral Product
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg Capsules, 12-15mg/ day for 3 days
Study: NCT01393821
Drug: menadione topical lotion
Normalized name: Menadione
DrugBank: Menadione (DB00170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT00752427
Drug: Paliperidone ER OROS®
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02213627
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03401346
Drug: Dihydroergotamine Mesylate (DHE)
Normalized name: Dihydroergotamine Mesylate
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine Mesylate (DHE) injection (intravenous)
Study: NCT03837223
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
Study: NCT01614886
Drug: Active Comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
Study: NCT01245556
Drug: BMS-908662
Normalized name: BMS-908662
DrugBank: BMS-908662 (DB12854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
Study: NCT01245556
Drug: BMS-908662
Normalized name: BMS-908662
DrugBank: BMS-908662 (DB12854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
Study: NCT01245556
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
Study: NCT01245556
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
Study: NCT00968565
Drug: sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
Study: NCT00761995
Drug: Azopt
Normalized name: Azopt
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical eye drop dosed 1 drop 3 times daily
Study: NCT00761995
Drug: Cosopt
Normalized name: Cosopt
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical eye drop dosed 1 drop 2 times daily
Study: NCT00349518
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01011894
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
Study: NCT04082520
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04064190
Drug: Vactosertib(TEW-7197)/ Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
Study: NCT01139645
Drug: Rabeprazole or Esomeprazole or Lanzoprazole
Normalized name: Medicated Pad or Tape
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
Study: NCT03755310
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First week: 10 mg tabs; Second week: 10-20 mg tabs
Study: NCT01469169
Drug: Iloprost (Ventavis inhaled, BAYQ6256)
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
Study: NCT00260533
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dose, up to 50 mg per day
Study: NCT00193076
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine
Study: NCT00193076
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin
Study: NCT00193076
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab
Study: NCT02486458
Drug: 5% sodium fluoride varnish
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
Study: NCT02486458
Drug: 1.23% sodium fluoride acidic gel
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
Study: NCT00001422
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03960788
Drug: Gadoxetate Sodium
Normalized name: gadoxetate
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
Study: NCT00424710
Drug: ranibizumab intravitreal injection
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year